Alzamend Neuro cuts preferred stock financing to $10 million from $25 million in amended agreement

• Alzamend Neuro amended its Series D convertible preferred stock financing with affiliate Ault Lending on November 10, 2026, reducing it to $10 million from $25 million.
• The revised agreement requires a $2.5 million second tranche, following the initial $7.5 million purchase on July 31, 2026.
• Conversion pricing is 80% of the lowest closing bid over five preceding trading days, with a $0.2668 floor and $2 cap.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-013930), on November 10, 2026, and is solely responsible for the information contained therein.